Defining On-Treatment Remission in Plaque Psoriasis: A Consensus Statement From the National Psoriasis Foundation

Psoriasis

Joint Position Statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on Routine Testing for Latent Tuberculosis Infection Prior To and During Treatment of Psoriasis Patients with IL-17 or IL-23 Inhibitors

J Am Acad Dermatol

Blauvelt A, Strober BE, Eakin GS, McCormick Howard L, Langan C, van de Kerkhof PCM, Puig L, Lebwohl MG, Romiti R, Armstrong AW, Choon SE, Ramessur R, Gelfand JM, Merola JF, Winthrop KL, Torres T

doi: 10.1016/j.jaad.2025.11.033

Psoriasis

Systemic Pharmacological Treatments for Chronic Plaque Psoriasis

JAMA Dermatol

Armstrong AW, Nong Y, Merola JF

doi: 10.1001/jamadermatol.2026.0200

Vitiligo

Definition of Severity and Relapse for Vitiligo: An International Consensus Statement

JAMA Dermatol

Eleftheriadou V, Desai S, Bae JM, Taylor S, Meurant JM, Abdallah M, Ju HJ, Benzekri L, Wolkerstorfer A, Böhm M, Xiang LF, Rush E, Hamzavi IH, Passeron T, Lim H, Harris JE, Parsad D, Huggins R, Schneider A, Kolios A, Rosmarin D, Mohammad TF, Esmat SM, Jones J, Retzer A, Seneschal J, Gkini MA, Ahmed A, Thompson A, Pandya AG, Cruz Rivera S, Kpenou FC, Ezzedine K, INTERCEPT Study Group and the Global Vitiligo Atlas

doi: 10.1001/jamadermatol.2026.0294

Psoriasis

Long-term safety and efficacy of secukinumab in paediatric severe plaque psoriasis: 236-week, Phase 3 trial results

J Eur Acad Dermatol Venereol

Kaszuba A, Papanastasiou P, Krasowska D, De Lucas Laguna R, Ziv M, Ravichandran S, Bansal A, Dahale SS, Martin R, Paguet B, Magnolo N, Kingo K

doi: 10.1111/jdv.70155

Psoriasis

Real-world treatment patterns in patients with generalized pustular psoriasis (GPP)

J Am Acad Dermatol

Strober B, Kwiatkowski H, Lavasani L, Semeco J, Lakshminarasimhan B, Lebwohl M, Gottlieb AB

doi: 10.1016/j.jaad.2025.08.089

Psoriatic Arthritis

Global Recruiting Patterns Affect Placebo Response Rates In Clinical Trials of Psoriatic Arthritis and Plaque Psoriasis

Arthritis Rheumatol

Kerschbaumer A, Steiner M, Khalili S, Shehab A, Jordanov A, Wildner B, Maad M, Smolen JS, Aletaha D

doi: 10.1002/art.43302

Psoriasis

Drug survival of systemic treatments for severe paediatric psoriasis: An international retrospective study

J Eur Acad Dermatol Venereol

Miao Y, Beauchet A, Piram M, McPherson T, Torres T, Yesli Y, Aubert H, Bodemer C, Bertoli C, Tardieu M, Hubiche T, Bonniaud B, Neri I, Chessa MA, Lasek A, Prignano F, Barbarot S, Bursztejn AC, Leducq S, Sergeant M, Puzenat E, Chiaverini C, Sigg N, Mallet S, Miquel J, Pourchot D, Patel KX, Burden-Teh E, Flohr C, Di Lernia V, Mahé E, GrPso of the Société Française de Dermatologie; Groupe de Recherche de la Société Française de Dermatologie Pédiatrique

doi: 10.1111/jdv.70108

Psoriasis

Efficacy and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: 52-week results from the SPROUT randomized controlled trial

Br J Dermatol

Paller AS, Fiorillo L, Becker E, Armesto S, Kontzias A, Oberoi RK, Zhang W, Amouzadeh H, Zhang Z, Arkin L

doi: 10.1093/bjd/ljaf305

Psoriasis

Three-Year Patient-Reported Outcomes From Bimekizumab for Plaque Psoriasis: The BE RADIANT Randomized Clinical Trial With Open-Label Extension

JAMA Dermatol

Augustin M, Feldman SR, Warren RB, Armstrong A, Vender R, López-Ferrer A, Dawe WH, Lambert J, Szilagyi B, Hoepken B, Warham R, Gottlieb AB

doi: 10.1001/jamadermatol.2025.6055

Related content

Joint Position Statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on Routine Testing for Latent Tuberculosis Infection Prior To and During Treatment of Psoriasis Patients with IL-17 or IL-23 Inhibitors

Systemic Pharmacological Treatments for Chronic Plaque Psoriasis

Definition of Severity and Relapse for Vitiligo: An International Consensus Statement

Long-term safety and efficacy of secukinumab in paediatric severe plaque psoriasis: 236-week, Phase 3 trial results

Real-world treatment patterns in patients with generalized pustular psoriasis (GPP)

Global Recruiting Patterns Affect Placebo Response Rates In Clinical Trials of Psoriatic Arthritis and Plaque Psoriasis

Drug survival of systemic treatments for severe paediatric psoriasis: An international retrospective study

Efficacy and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: 52-week results from the SPROUT randomized controlled trial

Three-Year Patient-Reported Outcomes From Bimekizumab for Plaque Psoriasis: The BE RADIANT Randomized Clinical Trial With Open-Label Extension